Regulator : Late-Stage

Late-Stage Regulatory Engagement

Execution Readiness & Submission Support

Late-stage engagement ensures that the finalized protocol is ready for execution and formal review. Conversations during this phase are focused on clarity, consistency, and readiness—minimizing the risk of delays, questions, or holds as the study moves into regulatory submission and trial initiation.

Late-stage engagement typically focuses on:

Final protocol clarifications and documentation alignment
Confirmation of safety oversight and risk mitigation strategies
Data standards, submission requirements, and inspection readiness
Assessment of operational elements that may impact compliance
Alignment on any deviations from previously discussed design elements

Late-Stage Federal Drug Administration (FDA) Meetings

Late-stage FDA meetings provide a formal mechanism to confirm that key clinical, statistical, and regulatory expectations are aligned as the development program advances toward pivotal studies and submission planning. At this point in development, structured interactions with the FDA help sponsors validate readiness, confirm incorporation of prior feedback, and address remaining issues that could affect the adequacy of the evidence package or submission strategy. These meetings play a key role in reinforcing design and execution confidence and supporting an efficient transition from late‑stage development to regulatory submission.

Scope and Use of This Roadmap

This section provides a high-level overview of formal FDA meeting pathways and selected regulatory programs commonly used during late-stage protocol development. It does not reflect informal or interim discussions that may occur with FDA review divisions outside of these established mechanisms. In addition, this roadmap is written assuming a traditional Phase 1, Phase 2, and Phase 3 drug development pathway. Programs that follow alternative or accelerated development approaches may require adaptation of the timing, sequencing, or types of regulatory engagement described here.

End of Phase 2 (EOP2) Meeting

Definition

An FDA End of Phase 2 (EOP2) Meeting is a formal milestone meeting between a drug sponsor and the FDA, held after Phase 2 trials and before Phase 3, to review safety, efficacy, and dose selection data; agree on Phase 3 study design to support future approval; and address regulatory requirements including CMC, nonclinical studies, and special considerations.

Purpose

To confirm that Phase 2 data supports progression to Phase 3, discuss and align on Phase 3 study design and statistical plans, identify any additional data needs, and ensure regulatory agreement on requirements for eventual approval.

EOP2 Meetings review several topics:

Safety and efficacy review from Phase 2.
Dose selection and justification for Phase 3.
Phase 3 protocol design (endpoints, sample size, statistical analysis).
Regulatory alignment on requirements for NDA/BLA submission.

Common Characteristics

Timing: After Phase 2 completion, before Phase 3 initiation.
Format: Teleconference, videoconference, or face-to-face.
FDA Response Time: Typically scheduled within 70 days of request.
Participants: Sponsor’s clinical, nonclinical, CMC, biostatistics, and regulatory teams; FDA review division (clinical, statistical, CMC, pharmacology/toxicology).
Focus: Review Phase 2 safety, efficacy, and dose selection; align on Phase 3 design; identify additional data needs; confirm regulatory requirements for approval.
Outcome: FDA provides written feedback and official meeting minutes summarizing agreements and recommendations.

Consider Bringing

Cover Letter & Meeting Request
Agenda & List of Questions for FDA
Background Information
- Drug overview (mechanism of action, indication)
- Summary of development program
Phase 2 Clinical Data
- Safety and efficacy results
- Dose-response analysis
- Pharmacokinetics/pharmacodynamics (PK/PD)
Proposed Phase 3 Plan
- Draft protocols
- Endpoints and statistical analysis plan
- Inclusion/exclusion criteria
Regulatory Elements
- Chemistry, Manufacturing, and Controls (CMC) summary
- Nonclinical study updates
- Risk management considerations
- Pediatric study plans (if applicable)
Supporting Documents
- Integrated Summary Tables
  - Adverse events, efficacy outcomes, exposure data
- Key Figures
  - Dose-response curves, Kaplan-Meier plots, PK profiles
- References
  - Relevant literature or prior FDA feedback
Team Preparation
- Bring subject matter experts:
  - Clinical lead, biostatistician, regulatory affairs, CMC lead, safety expert
- Prepare slides for discussion (concise, aligned with briefing package)

Considerations

Schedule EOP2 once sufficient Phase 2 data is available for review.

Pre-NDA/BLA Meeting

Definition

An FDA Pre-NDA/BLA Meeting is a formal meeting between a drug sponsor and the U.S. Food and Drug Administration (FDA) held near the end of the clinical development program, before submission of a New Drug Application (NDA) or Biologics License Application (BLA).

Purpose

To discuss the format, content, and organization of the application, address any outstanding issues from clinical, nonclinical, and CMC data, and confirm that the planned submission will meet regulatory requirements for review.

Topic Examples:

Unresolved issues
Trials to support quality, safety, and efficacy
Pediatric studies
Data summary
Data format and presentation
Drug name review
New molecular entities (NMEs)
Preliminary discussions of risk management plans, post-marketing studies, or trials
Quality information and inspection considerations
Outline of data to be submitted for abuse potential assessment and drug scheduling
For NMEs/original BLAs, agreements on the contents of a complete application, and late submission application components (up to 30 days after original submission)

Common Characteristics

Timing: Near the end of Phase 3 development, before submission of NDA or BLA.
Format: Teleconference, videoconference, or face-to-face.
FDA Response Time: Typically scheduled within 70 days of request.
Participants: Sponsor’s clinical, nonclinical, CMC, biostatistics, and regulatory teams; FDA review division.
Focus: Discuss format, content, and organization of the NDA/BLA; address outstanding clinical, nonclinical, and CMC issues; confirm readiness for submission.
Outcome: FDA provides written feedback and official meeting minutes summarizing agreements and recommendations

Consider Bringing

Cover Letter & Meeting Request
Agenda and List of Questions for FDA
Summary of Development Program (clinical, nonclinical, CMC)
Final Phase 3 Data (efficacy, safety, PK/PD)
Integrated Summaries (ISS/ISE)
Proposed NDA/BLA Structure (table of contents, electronic format)
Outstanding Issues (risk management, pediatric plans)
Slides for Discussion (aligned with briefing package)
Printed Copies of briefing package and presentation
Reference Documents (FDA guidance, prior feedback)
Subject Matter Experts (clinical, regulatory, biostatistics, CMC, safety)

Type C Meeting

Definition

A Type C meeting is any meeting other than Type A, Type B, or Type D that addresses product development and review issues. These meetings often involve complex or novel scientific and regulatory topics that require FDA input outside standard milestones.

Purpose

To provide early consultation between FDA review teams and sponsors on specialized development issues

Example: discuss biomarkers as a new surrogate endpoint:

FDA and industry believe that early consultation between review teams and sponsors is important for development programs where the sponsor intends to use a biomarker as a new surrogate endpoint that has never been previously used as the primary basis for product approval in the proposed context of use.
The purpose of this meeting is to discuss the feasibility of the surrogate as a primary endpoint and identify any gaps in knowledge and how they might be addressed.
Must include preliminary human data indicating impact of the drug on the biomarker at a dose that appears to be generally tolerable.

Example: Ongoing discussion of a Clinical Outcome Assessment development and use:

FDA and industry believe that early consultation between review teams and sponsors is important for development programs where the sponsor intends to use a Clinical Outcome Assessment (COA) as an endpoint that has never been previously used as the primary basis for product approval in the proposed context of use.
The purpose of this meeting is to discuss the feasibility of the COA as an endpoint and identify any gaps in knowledge and how they might be addressed.

Common Characteristics

Early engagement: Occurs before pivotal trials when novel endpoints or strategies are proposed.
Focused discussion: Centers on feasibility, scientific validity, and regulatory acceptability of new approaches.
Data-driven: Requires preliminary evidence to support discussion (e.g., human data showing drug impact on biomarker at a tolerable dose).
Collaborative: FDA and sponsor work together to identify gaps and next steps.

Consider Bringing

Meeting Request Letter: Clearly state objectives and rationale for the meeting.
Briefing Package: Submitted at least 30 days before the meeting, including:
- Background on the biomarker or COA and its proposed context of use.
- Preliminary human data showing drug impact on the biomarker or COA at a dose that appears tolerable.
- Scientific justification for why the endpoint could serve as a surrogate or primary measure.
- Specific questions for FDA focused on feasibility and regulatory considerations.
Supporting Data: Summaries of nonclinical and clinical findings relevant to the discussion.
Subject Matter Experts: Clinical, statistical, and regulatory experts prepared to address FDA questions.

Considerations

These points align with FDA’s official guidance on Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products and the examples you provided.

Resources for Regulatory Engagement

Formal PDUFA Meetings with FDA References

Website

Frequently asked questions on the PIND meeting

End of Phase 1 Meeting References

21 CFR 312.82(b)
21 CFR part 312, subpart E
21 CFR part 314, subpart H or I
21 CFR part 601, subpart E or H

Guidance for Industry

End-of-Phase 2A Meetings

End of Phase 2 Meeting References

Pre-NDA/BLA Meeting Questions References

21 CFR 312.47b(2)

Guidances for Industry

Submitting Meeting Request References

CTTI

Clinical Trials Transformation Initiative

Regulator : Late-Stage

Regulator : Late-Stage

Trial Design Stage

Late-Stage Regulatory Engagement

Late-Stage Federal Drug Administration (FDA) Meetings

Scope and Use of This Roadmap

Definition

Purpose

Common Characteristics

Consider Bringing

Considerations

Definition

Purpose

Common Characteristics

Consider Bringing

Definition

Purpose

Common Characteristics

Consider Bringing

Considerations

Resources for Regulatory Engagement